Literature DB >> 17706946

Sensitivity of the hypothalamic paraventricular nucleus to the locomotor-activating effects of neuromedin U in obesity.

Colleen M Novak1, Minzhi Zhang, James A Levine.   

Abstract

Obesity is associated with a decrease in energy expenditure relative to energy intake. The decrease in physical activity associated with obesity in several species, including humans, contributes to decreased energy expenditure. Several hormones and neuropeptides that affect appetite also modulate physical activity, including neuromedin U (NMU), a peptide found in the gut and brain. We have demonstrated that NMU microinjected into the hypothalamic paraventricular nucleus (PVN) in rats increases the energy expenditure associated with physical activity, called non-exercise activity thermogenesis (NEAT). Here we examined whether obesity in rats is related to decreased sensitivity of the PVN to the locomotor-activating effect of NMU. Diet-induced obese (DIO) rats and lean, diet-resistant (DR) rats were given PVN microinjections of increasing doses of NMU both before and after 1 month on a high-fat diet. We found that NMU increases physical activity, energy expenditure, and NEAT in a dose-dependent manner in both DR and DIO rats, both before and after 1 month on the high-fat diet. Before high-fat feeding, the obesity-prone and lean rats showed similar levels of physical activity after intra-PVN microinjections of NMU. After 1 month of the high-fat diet, however, the obesity-resistant rats showed significantly more NMU-induced physical activity compared to the obese DIO rats. Taken together with previous studies, these results suggest that obesity may represent a state associated with decreased central sensitivity to neuropeptides such as NMU that increase physical activity and therefore energy expenditure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706946      PMCID: PMC2735201          DOI: 10.1016/j.brainres.2007.06.055

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  97 in total

1.  Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice.

Authors:  T J Kowalski; B D Spar; L Markowitz; M Maguire; A Golovko; S Yang; C Farley; J A Cook; G Tetzloff; L Hoos; R A Del Vecchio; T M Kazdoba; M F McCool; J J Hwa; L A Hyde; H Davis; G Vassileva; J A Hedrick; E L Gustafson
Journal:  J Endocrinol       Date:  2005-04       Impact factor: 4.286

2.  Localization of 7B2, neuromedin B, and neuromedin U in specific cell types of rat, mouse, and human pituitary, in rat hypothalamus, and in 30 human pituitary and extrapituitary tumors.

Authors:  J H Steel; S Van Noorden; J Ballesta; S J Gibson; M A Ghatei; J Burrin; U Leonhardt; J Domin; S R Bloom; J M Polak
Journal:  Endocrinology       Date:  1988-01       Impact factor: 4.736

3.  Reduced paraventricular nucleus norepinephrine responsiveness in obesity-prone rats.

Authors:  B E Levin
Journal:  Am J Physiol       Date:  1996-02

4.  Corticotropin releasing factor produces behavioural activation in rats.

Authors:  R E Sutton; G F Koob; M Le Moal; J Rivier; W Vale
Journal:  Nature       Date:  1982-05-27       Impact factor: 49.962

5.  The reinforcing property and the rewarding aftereffect of wheel running in rats: a combination of two paradigms.

Authors:  Terry W Belke; Jason P Wagner
Journal:  Behav Processes       Date:  2005-02-28       Impact factor: 1.777

6.  Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats.

Authors:  L S Brady; M A Smith; P W Gold; M Herkenham
Journal:  Neuroendocrinology       Date:  1990-11       Impact factor: 4.914

7.  Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in rats.

Authors:  Kohji Kiwaki; Catherine M Kotz; Chuanfeng Wang; Lorraine Lanningham-Foster; James A Levine
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-12-02       Impact factor: 4.310

8.  Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial).

Authors:  Marleen A van Baak; Edgar van Mil; Arne V Astrup; Nick Finer; Luc F Van Gaal; Jannik Hilsted; Peter G Kopelman; Stephan Rössner; W Philip James; Wim H M Saris
Journal:  Am J Clin Nutr       Date:  2003-08       Impact factor: 7.045

9.  Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rat.

Authors:  C M Kotz; J E Briggs; M K Grace; A S Levine; C J Billington
Journal:  Am J Physiol       Date:  1998-08

10.  Hypothalamic actions of neuromedin U.

Authors:  A M Wren; C J Small; C R Abbott; P H Jethwa; A R Kennedy; K G Murphy; S A Stanley; A N Zollner; M A Ghatei; S R Bloom
Journal:  Endocrinology       Date:  2002-11       Impact factor: 4.736

View more
  12 in total

1.  Spontaneous activity, economy of activity, and resistance to diet-induced obesity in rats bred for high intrinsic aerobic capacity.

Authors:  Colleen M Novak; Carlos Escande; Paul R Burghardt; Minzhi Zhang; Maria Teresa Barbosa; Eduardo N Chini; Steven L Britton; Lauren G Koch; Huda Akil; James A Levine
Journal:  Horm Behav       Date:  2010-03-27       Impact factor: 3.587

2.  Neuromedin S and U.

Authors:  Colleen M Novak
Journal:  Endocrinology       Date:  2009-07       Impact factor: 4.736

Review 3.  Peptides and their potential role in the treatment of diabetes and obesity.

Authors:  Hannah C Greenwood; Stephen R Bloom; Kevin G Murphy
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 4.  Neuropeptides controlling energy balance: orexins and neuromedins.

Authors:  Joshua P Nixon; Catherine M Kotz; Colleen M Novak; Charles J Billington; Jennifer A Teske
Journal:  Handb Exp Pharmacol       Date:  2012

Review 5.  Regulation of appetite to treat obesity.

Authors:  Gilbert W Kim; Jieru E Lin; Michael A Valentino; Francheska Colon-Gonzalez; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

6.  Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.

Authors:  Michael A Valentino; Francheska Colon-Gonzalez; Jieru E Lin; Scott A Waldman
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 7.  Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.

Authors:  J D Mitchell; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

8.  The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).

Authors:  Andrea Peier; Jennifer Kosinski; Kimberly Cox-York; Ying Qian; Kunal Desai; Yue Feng; Prashant Trivedi; Nicholas Hastings; Donald J Marsh
Journal:  Endocrinology       Date:  2009-03-26       Impact factor: 4.736

9.  A Zebrafish Genetic Screen Identifies Neuromedin U as a Regulator of Sleep/Wake States.

Authors:  Cindy N Chiu; Jason Rihel; Daniel A Lee; Chanpreet Singh; Eric A Mosser; Shijia Chen; Viveca Sapin; Uyen Pham; Jae Engle; Brett J Niles; Christin J Montz; Sridhara Chakravarthy; Steven Zimmerman; Kourosh Salehi-Ashtiani; Marc Vidal; Alexander F Schier; David A Prober
Journal:  Neuron       Date:  2016-02-17       Impact factor: 17.173

Review 10.  Brain orexin promotes obesity resistance.

Authors:  Catherine Kotz; Joshua Nixon; Tammy Butterick; Claudio Perez-Leighton; Jennifer Teske; Charles Billington
Journal:  Ann N Y Acad Sci       Date:  2012-07-17       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.